Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy

Phase 2 Completed 58 enrolled Morphotek

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if an investigational drug called MORAb-003 is useful by itself or when used with other approved cancer drugs in treating women with ovarian cancer. MORAb-003 is a monoclonal antibody directed against an antigen on most ovarian cancers.

Timeline

Start: 2006-05
Primary completion: 2010-02
Completion: 2010-06

Publications

Armstrong DK, White AJ, Weil SC, Phillips M, Coleman RL. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol. 2013 Jun;129(3):452-8. doi: 10.1016/j.ygyno.2013.03.002. Epub 2013 Mar 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Farletuzumab	Monoclonal antibody	100 mg/m2	—
Background	Carboplatin	Small molecule	5 unknown	Intravenous
Background	Carboplatin	Small molecule	6 unknown	Intravenous
Background	Docetaxel	Small molecule	75 mg/m2	—
Background	Paclitaxel	Small molecule	175 mg/m2	—

Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy

Summary

Timeline

Publications

Drugs

Indications